Skip to main content

Table 1 Patients characteristics at the initiation of first-line chemotherapy

From: Combination versus single-agent as palliative chemotherapy for gastric cancer

CharacteristicsBefore propensity score matchingP valueAfter propensity score matchingP value
Total N (%)ChemotherapyTotal N (%)Chemotherapy
Single-agentCombinationSingle-agentCombination
Gender   0.101   0.672
 Male478 (69.6)107(64.5)371 (71.2) 164 (69.5)80(67.8)84 (71.2) 
 Female209 (30.4)59 (35.5)150 (28.8) 72 (30.5)38 (32.2)34 (28.8) 
Age (years)   < 0.0001   0.88
  < 70562 (81.8)94 (56.6)468 (89.8) 160 (67.8)79 (66.9)81 (68.6)9
  ≥ 70125 (18.2)72 (43.4)53 (10.2) 76 (32.2)39 (33.1)37 (31.4) 
PS (ECOG)   < 0.0001   0.865
 0, 1611 (88.9)116 (69.9)495 (95.0) 194 (82.2)98 (83.1)96 (81.4) 
 2, 376 (11.1)a50 (30.1)26 (5.0) 42 (17.8)a20 (16.9)22 (18.6) 
Disease status   0.325   0.696
 Primary metastatic383 (55.7)87 (52.4)296 (56.8) 116 (49.2)56 (47.5)60 (56.8) 
 Recurrent304 (44.3)79 (47.6)225 (43.2) 120 (50.8)62 (52.5)58 (49.2) 
 Tumor differentiation   0.111   0.933
 Well, moderate167 (24.3)50 (30.1)117 (22.5) 67 (28.4)34 (28.8)33 (28.0) 
 Poor186 (27.1)43 (25.9)143 (27.4) 61 (25.8)30 (25.4)31 (26.3) 
 Signet ring cell171 (24.9)32 (19.3)139 (26.7) 59 (25.0)28 (23.7)31 (26.3) 
 Combined, others163 (23.7)41 (24.7)122 (23.4) 49 (20.8)26 (22.0)23 (19.5) 
Peritoneal metastasis   0.003   0.686
 No373 (54.3)107 (64.5)266 (51.1) 148 (62.7)72 (61.0)76 (64.4) 
 Yes314 (45.7)59 (35.5)255 (48.9) 88 (37.3)46 (39.0)42 (35.6) 
Liver metastasis   0.915   0.382
 No535 (77.9)130 (78.3)405 (77.7) 171 (72.5)89 (75.4)82 (69.5) 
 Yes152 (22.1)36 (21.7)116 (22.3) 65 (27.5)29 (24.6)36 (30.5) 
Palliative surgical resection   0.182   0.731
 No549 (79.9)139 (83.7)410 (78.7) 195 (82.6)96 (81.4)99 (83.9) 
 Yes138 (20.1)27(16.3)111 (21.3) 41 (17.4)22 (18.6)19 (16.1) 
  1. a PS 3: 2 patients
  2. N number, PS performance status, ECOG Eastern Cooperative Oncology Group